Halozyme Therapeutics, Inc. · NASDAQ:HALO

Torley Helen sold 50,000 Halozyme Therapeutics, Inc. shares (Form 4)

Traded Jun 1 to Jun 3, 2026 · Filed Jun 3, 2026

From Jun 1 to Jun 3, 2026, Torley Helen (Director, PRESIDENT AND CEO) sold 50,000 Halozyme Therapeutics, Inc. shares at an average US$67.40 for US$3.37M under a trading plan, leaving 767,780 shares. Filed Jun 3, 2026 (Form 4).

Sold
50,000 shares
Price
US$67.40 average (US$66.31 to US$69.69)
Value
US$3.37M
Holding after
767,780 shares
Trading plan
Yes (Made under a plan set in advance)
Role
Director, PRESIDENT AND CEO

The filing in full

DateSecurityTransactionSharesPriceHolding afterOwnership
Jun 1, 2026Common StockOption exercise20,000US$12.07787,780Direct
Jun 1, 2026Common StockSale1,610US$66.39786,170Direct
Jun 1, 2026Common StockSale12,989US$67.41773,181Direct
Jun 1, 2026Common StockSale5,401US$68.35767,780Direct
Jun 2, 2026Common StockOption exercise20,000US$12.07787,780Direct
Jun 2, 2026Common StockSale16,600US$66.31771,180Direct
Jun 2, 2026Common StockSale3,400US$66.75767,780Direct
Jun 3, 2026Common StockOption exercise10,000US$12.07777,780Direct
Jun 3, 2026Common StockSale400US$66.37777,380Direct
Jun 3, 2026Common StockSale1,500US$67.68775,880Direct
Jun 3, 2026Common StockSale2,000US$68.74773,880Direct
Jun 3, 2026Common StockSale6,100US$69.69767,780Direct

Source

View original at SEC

Related